



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## MDL-29951

Cat. No.:	HY-16312
CAS No.:	130798-51-5
Molecular Formula:	C <sub>12</sub> H <sub>9</sub> Cl <sub>2</sub> NO <sub>4</sub>
Molecular Weight:	302.11
Target:	iGluR
Pathway:	Membrane Transporter/Ion Channel; Neuronal Signaling
Storage:	<div> <div>Powder</div> <div> <div>-20°C</div> <div>3 years</div> </div> </div> <div> <div>4°C</div> <div>2 years</div> </div> <div> <div>In solvent</div> <div> <div>-80°C</div> <div>2 years</div> </div> </div> <div> <div>-20°C</div> <div>1 year</div> </div>



## SOLVENT & SOLUBILITY

### In Vitro

DMSO : ≥ 50 mg/mL (165.50 mM)  
 \* "≥" means soluble, but saturation unknown.

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		3.3101 mL	16.5503 mL	33.1005 mL
	5 mM		0.6620 mL	3.3101 mL	6.6201 mL
	10 mM		0.3310 mL	1.6550 mL	3.3101 mL

Please refer to the solubility information to select the appropriate solvent.

### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: ≥ 2.5 mg/mL (8.28 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
Solubility: ≥ 2.5 mg/mL (8.28 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
Solubility: ≥ 2.5 mg/mL (8.28 mM); Clear solution

## BIOLOGICAL ACTIVITY

Description	MDL-29951 is a novel glycine antagonist of NMDA receptor activation, with K <sub>i</sub> of 0.14 μM for [ <sup>3</sup> H]glycine binding in vitro and in vivo.
IC <sub>50</sub> & Target	NMDA Receptor
In Vitro	MDL 100,748 and MDL 29,951 are approximately 2000-fold selective for the glycine binding site relative to the glutamate

recognition sites<sup>[1]</sup>. MDL-29951 is found to inhibit the human F16Bpase under these conditions ( $IC_{50}=2.5\text{ }\mu\text{M}$ ). MDL-29951 inhibits the human liver ( $IC_{50}=2.5\text{ }\mu\text{M}$ ), porcine kidney ( $IC_{50}=1.0\text{ }\mu\text{M}$ ), and rabbit liver ( $IC_{50}=0.21\text{ }\mu\text{M}$ ) isoforms of the enzyme, but is significantly less potent against the rat liver isoform ( $IC_{50}=11\text{ }\mu\text{M}$ )<sup>[2]</sup>. The MDL29951-activated receptor exhibits other activities associated with GPCR-mediated signaling, including G protein-dependent activation of extracellular signal-regulated kinase 1 and 2 (ERK1/2) and recruitment of  $\beta$ -arrestin. As with recombinant cell systems, MDL29951 promotes  $Ca^{2+}$  signaling responses and inhibition of cyclic adenosine monophosphate (cAMP) accumulation in rat oligodendrocyte precursor cells during the period of peak GPR17 abundance. Effects of MDL29951 are markedly reduced in cells with low GPR17 abundance and are blocked by pranlukast<sup>[3]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## PROTOCOL

### Kinase Assay <sup>[1]</sup>

[<sup>3</sup>H]JCPP (30.7 Ci/mmol) binding assays are conducted in minivials, incubated for 15 min at 25°C in 1 mL of 50 mM Tris-HCl (pH 7.4) containing 10 nM [<sup>3</sup>H]JCPP, 200 g of membrane protein and unlabeled ligands as indicated. Nonspecific binding is defined using 1 mM L-glutamate. Bound ligand is separated by centrifugation. Specific binding accounted for approximately 80% of total binding.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## CUSTOMER VALIDATION

- Cell Death Dis. 2021 Jun 12;12(6):610.
- J Neurosci. 2016 Oct 12;36(41):10560-10573.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

[1]. Baron BM, et al. Potent indole- and quinoline-containing N-methyl-D-aspartate antagonists acting at the strychnine-insensitive glycine binding site. J Pharmacol Exp Ther. 1992 Sep;262(3):947-56.

[2]. Wright SW, et al. 3-(2-carboxyethyl)-4,6-dichloro-1H-indole-2-carboxylic acid: an allosteric inhibitor of fructose-1,6-bisphosphatase at the AMP site. Bioorg Med Chem Lett. 2003 Jun 16;13(12):2055-8.

[3]. Harden TK. Enigmatic GPCR finds a stimulating drug. Sci Signal. 2013 Oct 22;6(298):pe34.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA